Download PDF
J Knee Surg 2021; 34(07): 749-754
DOI: 10.1055/s-0039-1700805
Original Article

One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty

Ryan S. Charette
1   Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
,
Jenna A. Bernstein
1   Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
,
Matthew Sloan
1   Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
,
Corbyn M. Nchako
2   Saint Louis University School of Medicine, Saint Louis, Missouri
,
Atul F. Kamath
1   Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
,
Charles L. Nelson
1   Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Tranexamic acid (TXA) has been shown to reduce blood loss and postoperative transfusions in total knee arthroplasty (TKA). There is no consensus on the ideal dosing regimen in the literature, although there is a growing body of literature stating there is little benefit to additional doses. Our study compared one versus two doses of TXA in primary TKA and its effect on postoperative transfusion rate. We retrospectively reviewed patients undergoing primary TKA at our two high-volume arthroplasty centers between 2013 and 2016. Patients were included if they underwent unilateral primary TKA, and received one or two doses of intravenous TXA. Patients receiving therapeutic anticoagulation were excluded. Our primary outcome was postoperative transfusion rate. Secondary outcomes included blood loss, length of stay, rate of deep vein thrombosis or pulmonary embolism (DVT/PE), readmission and reoperation.

A total of 1,191 patients were included: 891 received one dose and 300 received two doses. There was no significant difference in rate of transfusion, deep vein thrombosis or pulmonary embolism (DVT/PE), blood volume loss, and reoperation. There was a significantly higher risk of readmission (6.7 vs. 2.4%, odds ratio [OR] 2.96, p < 0.001) and reoperation (2.0 vs. 0.6%, OR 3.61, p = 0.024) in patients receiving two doses. These findings were similar with subgroup analysis of patients receiving only aspirin prophylaxis.

In unilateral TKA, there is no difference in transfusion rate with one or two doses of perioperative TXA. There was no increased risk of thromboembolic events between groups, although the two-dose group had a higher rate of readmission and reoperation. Given the added cost without clear benefit, these findings may support administration of one rather than two doses of TXA during primary TKA.

Keywords

total knee arthroplasty - tranexamic acid - blood transfusion


Publication History

Received: 20 September 2019

Accepted: 23 September 2019

Article published online:
15 November 2019

© 2019. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89 (04) 780-785
    CrossrefPubMedGoogle Scholar
  • 2 Husted H, Holm G, Jacobsen S. Predictors of length of stay and patient satisfaction after hip and knee replacement surgery: fast-track experience in 712 patients. Acta Orthop 2008; 79 (02) 168-173
    CrossrefPubMedGoogle Scholar
  • 3 Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. Knee 2000; 7 (03) 151-155
    CrossrefPubMedGoogle Scholar
  • 4 Cushner FD, Friedman RJ. Blood loss in total knee arthroplasty. Clin Orthop Relat Res 1991; (269) 98-101
    PubMedGoogle Scholar
  • 5 Guo P, He Z, Wang Y. et al. Efficacy and safety of oral tranexamic acid in total knee arthroplasty: a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97 (18) e0587
    CrossrefPubMedGoogle Scholar
  • 6 Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113 (15) 3406-3417
    CrossrefPubMedGoogle Scholar
  • 7 Klein HG. Allogeneic transfusion risks in the surgical patient. Am J Surg 1995; 170 (6A, Suppl): 21S-26S
    CrossrefPubMedGoogle Scholar
  • 8 Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50 (04) 753-765
    CrossrefPubMedGoogle Scholar
  • 9 Georgiadis AG, Muh SJ, Silverton CD, Weir RM, Laker MW. A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty. J Arthroplasty 2013; 28 (8, Suppl): 78-82
    CrossrefPubMedGoogle Scholar
  • 10 Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. Knee 2013; 20 (05) 300-309
    CrossrefPubMedGoogle Scholar
  • 11 MacGillivray RG, Tarabichi SB, Hawari MF, Raoof NT. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study. J Arthroplasty 2011; 26 (01) 24-28
    CrossrefPubMedGoogle Scholar
  • 12 Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br 2001; 83 (05) 702-705
    CrossrefPubMedGoogle Scholar
  • 13 Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br 1996; 78 (03) 434-440
    CrossrefPubMedGoogle Scholar
  • 14 Seol YJ, Seon JK, Lee SH. et al. Effect of tranexamic acid on blood loss and blood transfusion reduction after total knee arthroplasty. Knee Surg Relat Res 2016; 28 (03) 188-193
    CrossrefPubMedGoogle Scholar
  • 15 Hallstrom B, Singal B, Cowen ME, Roberts KC, Hughes RE. The Michigan experience with safety and effectiveness of tranexamic acid use in hip and knee arthroplasty. J Bone Joint Surg Am 2016; 98 (19) 1646-1655
    CrossrefPubMedGoogle Scholar
  • 16 Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am 2012; 94 (13) 1153-1159
    CrossrefPubMedGoogle Scholar
  • 17 Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93 (12) 1577-1585
    CrossrefPubMedGoogle Scholar
  • 18 Huang Z, Ma J, Shen B, Pei F. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty 2014; 29 (12) 2342-2346
    CrossrefPubMedGoogle Scholar
  • 19 Tuttle JR, Ritterman SA, Cassidy DB, Anazonwu WA, Froehlich JA, Rubin LE. Cost benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty. J Arthroplasty 2014; 29 (08) 1512-1515
    CrossrefPubMedGoogle Scholar
  • 20 Gilbody J, Dhotar HS, Perruccio AV, Davey JR. Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty 2014; 29 (04) 681-684
    CrossrefPubMedGoogle Scholar
  • 21 Konig G, Hamlin BR, Waters JH. Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty. J Arthroplasty 2013; 28 (09) 1473-1476
    CrossrefPubMedGoogle Scholar
  • 22 Fillingham YA, Ramkumar DB, Jevsevar DS. et al. Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. J Arthroplasty 2018; 33 (10) 3065-3069
    CrossrefPubMedGoogle Scholar
  • 23 Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 2012; 470 (09) 2605-2612
    CrossrefPubMedGoogle Scholar
  • 24 Lin PC, Hsu CH, Huang CC, Chen WS, Wang JW. The blood-saving effect of tranexamic acid in minimally invasive total knee replacement: is an additional pre-operative injection effective?. J Bone Joint Surg Br 2012; 94 (07) 932-936
    CrossrefPubMedGoogle Scholar
  • 25 Sun Q, Yu X, Wu J, Ge W, Cai M, Li S. Efficacy of a single dose an additional dose of tranexamic acid in reduction of blood loss in total knee arthroplasty. J Arthroplasty 2017; 32 (07) 2108-2112
    CrossrefPubMedGoogle Scholar
  • 26 Xie J, Ma J, Yao H, Yue C, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplasty 2016; 31 (11) 2458-2464
    CrossrefPubMedGoogle Scholar
  • 27 Gibon E, Courpied JP, Hamadouche M. Total joint replacement and blood loss: what is the best equation?. Int Orthop 2013; 37 (04) 735-739
    CrossrefPubMedGoogle Scholar
  • 28 Wilde JM, Copp SN, McCauley JC, Bugbee WD. One dose of intravenous tranexamic acid is equivalent to two doses in total hip and knee arthroplasty. J Bone Joint Surg Am 2018; 100 (13) 1104-1109
    CrossrefPubMedGoogle Scholar
  • 29 Tan J, Chen H, Liu Q, Chen C, Huang W. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res 2013; 184 (02) 880-887
    CrossrefPubMedGoogle Scholar
  • 30 Niskanen RO, Korkala OL. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop 2005; 76 (06) 829-832
    CrossrefPubMedGoogle Scholar